Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Menche, Jörg
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Schmidt, Harald H.H.W.
  • Oliva Miguel, Baldomero
  • Guney, Emre
The past decades have witnessed a paradigm shift from the traditional drug discovery shaped around the idea of "one target, one disease" to polypharmacology (multiple targets, one disease). Given the lack of clear-cut boundaries across disease (endo)phenotypes and genetic heterogeneity across patients, a natural extension to the current polypharmacology paradigm is to target common biological pathways involved in diseases via endopharmacology (multiple targets, multiple diseases). In this study, we present proximal pathway enrichment analysis (PxEA) for pinpointing drugs that target common disease pathways towards network endopharmacology. PxEA uses the topology information of the network of interactions between disease genes, pathway genes, drug targets and other proteins to rank drugs by their interactome-based proximity to pathways shared across multiple diseases, providing unprecedented drug repurposing opportunities. Using PxEA, we show that many drugs indicated for autoimmune disorders are not necessarily specific to the condition of interest, but rather target the common biological pathways across these diseases. Finally, we provide high scoring drug repurposing candidates that can target common mechanisms involved in type 2 diabetes and Alzheimer's disease, two conditions that have recently gained attention due to the increased comorbidity among patients., The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The authors also received support from EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate). E.G. was supported by EU-cofunded Beatriu de Pinós incoming fellowship from the Agency for Management of University and Research Grants (AGAUR) of Government of Catalunya and L.I.F. received support from ISCIII-FEDER (CPII16/00026). H.H.H.W.S. has received funding from from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777111 (Repotrial). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

On the Clinical Pharmacology of Reactive Oxygen Species

  • Casas, Ana I.
  • Nogales, Cristian
  • Mucke, Hermann A.M.
  • Petraina, Alexandra
  • Cuadrado Pastor, Antonio
  • Rojo Sanchís, Ana Isabel
  • Ghezzi, Pietro
  • Jaquet, Vincent
  • Augsburger, Fiona
  • Dufrasne, Francois
  • Soubhye, Jalal
  • Deshwal, Soni
  • Sante, Moises Di
  • Kaludercic, Nina
  • Lisa, Fabio Di
  • Schmidt, Harald H.H.W.
Reactive oxygen species (ROS) have been correlated with almost every human disease. Yet clinical exploitation of these hypotheses by pharmacological modulation of ROS has been scarce to nonexistent. Are ROS, thus, irrelevant for disease? No. One key misconception in the ROS field has been its consideration as a rather detrimental metabolic by-product of cell metabolism, and thus, any approach eliminating ROS to a certain tolerable level would be beneficial. We now know, instead, that ROS at every concentration, low or high, can serve many essential signaling and metabolic functions. This likely explains why systemic, nonspecific antioxidants have failed in the clinic, often with neutral and sometimes even detrimental outcomes. Recently, drug development has focused, instead, on identifying and selectively modulating ROS enzymatic sources that in a given constellation cause disease while leaving ROS physiologic signaling and metabolic functions intact. As sources, the family of NADPH oxidases stands out as the only enzyme family solely dedicated to ROS formation. Selectively targeting disease-relevant ROS-related proteins is already quite advanced, as evidenced by several phase II/III clinical trials and the first drugs having passed registration. The ROS field is expanding by including target enzymes and maturing to resemble more and more modern, big data–enhanced drug discovery and development, including network pharmacology. By defining a disease based on a distinct mechanism, in this case ROS dysregulation, and not by a symptom or phenotype anymore, ROS pharmacology is leaping forward from a clinical underperformer to a proof of concept within the new era of mechanism-based precision medicine, This study was supported by the European Research Council Advanced Investigator Grant/RadMed [Grant294683], Proof-of-Concept Grant/SAVEBRAIN[Grant737586] and H2020 Project REPO-TRIAL[Grant777111] (to H.H.H.W.S.) and short-term scientific mission sby the COST Actions EU-ROS and Open-MultiMed, and Kootstra Talented Fellowship (MaastrichtUniversity) (toA.I.C.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reactive oxygen comes of age: Mechanism-based therapy of diabetic end-organ damage

  • Elbatreek, Mahmoud H.
  • Pachado, Mayra P.
  • Cuadrado, Antonio
  • Jandeleit-Dahm, Karin
  • Schmidt, Harald H.H.W.
Reactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general., H.H.H.W.S. wishes to gratefully acknowledge funding by an ERC Advanced Investigator Grant (294683 – RadMed), an ERC proof-of-concept grant (139-101052 – SAVEBRAIN), and the EU Horizon 2020 programme, REPO-TRIAL. K.J.D. is supported by a fellowship of the National Health and Medical Research Council. A.C. is the recipient of grant SAF2016-76520-R from the Spanish Ministry of Economy and Competitiveness, P_37_732/2016 REDBRAIN from the European Regional Development Fund, and the Competitiveness Operational Program 2014-2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Joining European Scientific Forces to Face Pandemics

  • Vasconcelos, M. Helena
  • Alcaro, Stefano
  • Arechavala-Gameza, Virginia
  • Baumbach, Jan
  • Borges, Fernanda
  • Brevini, Tiziana A. L.
  • De Las Rivas, Javier
  • Devaux, Yvan
  • Hozak, Pavel
  • Keinänen-Toivola, Minna M.
  • Lattanzi, Giovanna
  • Mohr, Thomas
  • Murovska, Modra
  • Prusty, Bhupesh K.
  • Quinlan, Roy A.
  • Pérez-Sala, Dolores
  • Scheibenbogen, Carmen
  • Schmidt, Harald H.H.W.
  • Silveira, Isabel
  • Tieri, Paolo
  • Tolios, Alexander
  • Riganti, Chiara
Despite the international guidelines on the containment of the coronavirus disease 2019 (COVID-19) pandemic, the European scientific community was not sufficiently prepared to coordinate scientific efforts. To improve preparedness for future pandemics, we have initiated a network of nine European-funded Cooperation in Science and Technology (COST) Actions that can help facilitate inter-, multi-, and trans-disciplinary communication and collaboration., M.H.V. has grants from FEDER (Fundo Europeu de Desenvolvimento Regional) through COMPETE 2020 and from FCT (Foundation for Science and Technology; POCI-01-0145-FEDER-030457 ; POCI-01-0145-FEDER-016390 : CANCEL STEM). V.A-G. holds a Miguel Servet Fellowship from the ISCIII (CPII17/00004), part-funded by ERDF/FEDER , and acknowledges funding from Ikerbasque (Basque Foundation for Science). T.B. has grants from Carraresi Foundation , EU Horizon 2020 research and innovation programme No 828835 FetOpen and MIND Food’s HUB-Regione Lombardia. J.D.L.R. acknowledges funding from ISCIII (project PI18/00591 ) cofounded by the EU FEDER funds. D.P-S. has grants RTI2018-097624-B-I00 ( AEI, MCI, Spain, and ERDF ), RD16/0006/0021 ( ISCIII, Spain, and ERDF ), and CSIC PTI Global Health ( PIE 202020E223/CSIC-COV19-100 ). H.H.H.W.S. has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777111 (REPO-TRIAL). I.S. acknowledges funding from FCT (Fundação para a Ciência e Tecnologia), Portugal. C.R. is supported by AIRC (Italian Association for Cancer Research; IG21408 ). C.R. has funding from PharmaMar . Y.D. acknowledges funding from the National Research Fund (grants C14/BM/8225223 , C17/BM/11613033 , and COVID-19/2020-1/14719577/miRCOVID ), the Ministry of Higher Education and Research, and the Heart Foundation – Daniel Wagner of Luxembourg. P.T. acknowledges the support of H2020 project iPC “individualized Paediatric Cure” ( 826121 )., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Menche, Jörg
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Schmidt, Harald H.H.W.
  • Oliva Miguel, Baldomero
  • Guney, Emre
The past decades have witnessed a paradigm shift from the traditional drug discovery shaped around the idea of "one target, one disease" to polypharmacology (multiple targets, one disease). Given the lack of clear-cut boundaries across disease (endo)phenotypes and genetic heterogeneity across patients, a natural extension to the current polypharmacology paradigm is to target common biological pathways involved in diseases via endopharmacology (multiple targets, multiple diseases). In this study, we present proximal pathway enrichment analysis (PxEA) for pinpointing drugs that target common disease pathways towards network endopharmacology. PxEA uses the topology information of the network of interactions between disease genes, pathway genes, drug targets and other proteins to rank drugs by their interactome-based proximity to pathways shared across multiple diseases, providing unprecedented drug repurposing opportunities. Using PxEA, we show that many drugs indicated for autoimmune disorders are not necessarily specific to the condition of interest, but rather target the common biological pathways across these diseases. Finally, we provide high scoring drug repurposing candidates that can target common mechanisms involved in type 2 diabetes and Alzheimer's disease, two conditions that have recently gained attention due to the increased comorbidity among patients., The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The authors also received support from EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate). E.G. was supported by EU-cofunded Beatriu de Pinós incoming fellowship from the Agency for Management of University and Research Grants (AGAUR) of Government of Catalunya and L.I.F. received support from ISCIII-FEDER (CPII16/00026). H.H.H.W.S. has received funding from from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777111 (Repotrial). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370)